TG Therapeutics, Inc. vs ADMA Biologics, Inc.: Annual Revenue Growth Compared

Biotech Revenue Growth: ADMA vs. TG Therapeutics

__timestampADMA Biologics, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20145915545152381
Thursday, January 1, 20157177633152381
Friday, January 1, 201610661037152381
Sunday, January 1, 201722760560152381
Monday, January 1, 201816985290152000
Tuesday, January 1, 201929349083152000
Wednesday, January 1, 202042219783152000
Friday, January 1, 2021809426256689000
Saturday, January 1, 20221540796922785000
Sunday, January 1, 2023258214999233662000
Loading chart...

Data in motion

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and potential. Over the past decade, ADMA Biologics, Inc. and TG Therapeutics, Inc. have showcased contrasting trajectories in their annual revenue growth. Starting in 2014, ADMA Biologics reported a modest revenue of approximately $5.9 million, which surged to an impressive $258 million by 2023. This represents a staggering growth of over 4,200%, highlighting ADMA's robust expansion and market penetration.

Conversely, TG Therapeutics experienced a more volatile journey. From a steady revenue of around $152,000 between 2014 and 2020, the company saw a dramatic increase to $233 million in 2023. This leap underscores TG Therapeutics' breakthrough in recent years, possibly due to successful product launches or strategic partnerships. These trends reflect the ever-evolving landscape of the biotech industry, where innovation and adaptability are paramount.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025